DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma

  • Yuan, Sheng-Guang (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Liao, Wei-Jia (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Yang, Jian-Jun (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Huang, Guo-Jin (Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair) ;
  • Huang, Zhao-Quan (Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair)
  • Published : 2015.01.22


Background: This study was conducted to determine DEPDC1 expression in hepatocelluar carcinomas (HCCs) and to reveal its potential role in diagnosis and prognosis of affected patients. Materials and Methods: DEPDC1 expression at the mRNA level was detected by quantitative real-time PCR (qRT-PCR) in 205 cases of HCC and paired adjacent normal liver tissues, and by semi-quantitative RT-PCR in 20 cases. Survival curves were obtained by using Kaplan-Meier method and Log-rank test. Independent predictors associated with regard to disease free survival (DFS) and overall survival (OS) were identified using the Cox proportional hazard model. Results: High DEPDC1 mRNA levels were detected in 144 out of 205 cases (70.24%) of HCC, significantly associated with clinicopathological parameters, including tumor size (${\geq}4cm$), alpha-fetoprotein (${\geq}100ng/ml$), B-C of BCLC stage and recurrence. Kaplan-Meier survival analysis revealed that HCC patients with high DEPDC1 expression had poor OS and DFS. Multivariate analysis demonstrated that high DEPDC1 expression was an independent predictor for OS (HR=1.651; 95% 95%CI, 1.041-2.617; p=0.033) and DFS (HR=1.583; 95%CI, 1.01-2.483; p=0.045). Conclusions: Our results indicate DEPDC1 might be a novel diagnostic marker and an independent prognostic predictor for HCC patients.


Supported by : National Natural Science Foundation of China


  1. Ballon DR, Flanary PL, Gladue DP, et al (2006). DEP-domain-mediated regulation of gpcr signaling responses. Cell, 126, 1079-93.
  2. Cheng CH, Lee CF, Wu TH, et al (2011). Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol, 9, 114.
  3. Ercolani G, Grazi GL, Ravaioli M, et al (2003). Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg, 237, 536-43.
  4. Fazeli Z, Pourhoseingholi MA, Vahedi M, et al (2012). Burden of hepatocellular carcinoma in Asia. Asian Pac J Cancer Prev, 13, 5955-8.
  5. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
  6. Harada Y, Kanehira M, Fujisawa Y, et al (2010). Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res, 70, 5829-39.
  7. Ji D, Lu Z-T, Li Y-Q, et al (2014). MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma. Asian Pac J Cancer Prev, 15, 999-1003.
  8. Kanehira M, Harada Y, Takata R, et al (2007). Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene, 26, 6448-55.
  9. Kassambara A, Schoenhals M, Moreaux J, et al (2013). Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One, 8, 62752.
  10. Kharrat A, Millevoi S, Baraldi E, et al (1998). Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim Biophys Acta, 1385, 157-64.
  11. Kobayashi A, Kawasaki S, Miyagawa S, et al (2006). Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterol, 53, 736-41.
  12. Kretschmer C, Sterner-Kock A, Siedentopf F, et al (2011). Identification of early molecular markers for breast cancer. Mol Cancer, 10, 15.
  13. Liao W, Liu W, Yuan Q, et al (2013). Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One, 8, 80789.
  14. Obara W, Ohsawa R, Kanehira M, et al (2012). Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol, 42, 591-600.
  15. Okayama H, Kohno T, Ishii Y, et al (2012). Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res, 72, 100-11.
  16. Peng SY, Chen WJ, Lai PL, et al (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer, 112, 44-50.
  17. Sendoel A, Maida S, Zheng X, et al (2014). DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol, 16, 812-20.
  18. Sokol S (2000). A role for Wnts in morpho-genesis and tissue polarity. Nat Cell Biol, 2, 124-5.
  19. Tandon P, Garcia-Tsao G (2009). Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int, 29, 502-10.
  20. Tralhao JG, Dagher I, Lino T, et al (2007). Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol, 33, 746-51.
  21. Wang T, Hu HS, Feng YX, et al (2010). Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer, 102, 1618-26.

Cited by

  1. Validation and ranking of seven staging systems of hepatocellular carcinoma vol.14, pp.1, 2017,
  2. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma vol.5, pp.12, 2018,